Prostate Cancer Market to Become Increasingly Crowded, According to the Report by FirstWord

26 Apr 2013 • by Natalie Aster

Examination of the most prominent insights gained from six key opinion leaders (KOLs) from North America and six KOLs from Europe is available in the new research report “KOL Insight: Prostate Cancer: Competition intensifies in race to the top” by FirstWord. Results of FirstWord’s research and analysis for KOL Insight: Prostate Cancer identified the following major findings:

New androgen inhibitors have boosted the worldwide market value – Over the last few years, the worldwide prostate cancer market has been declining as generic erosion has taken hold of the existing therapies. However, recent launches of new androgen inhibitors, such as Zytiga (abiraterone acetate; Johnson & Johnson) and Xtandi (enzalutamide; Medivation/Astellas), has stemmed this loss in revenue and will boost the market value of this disease;

Improving survival rates in patients with metastatic castration-resistant prostate cancer is the number one unmet need – Interviewed KOLs felt the most prominent unmet need is for more effective therapies in patients with metastatic castration-resistant prostate cancer. KOLs also highlighted the need for biomarkers to identify the most suitable therapies for individual patients, more tolerable agents, and better understanding of the disease;

Zytiga and Xtandi will dominate the post and pre-chemo segments – Recently approved androgen inhibitors demonstrate impressive efficacy and tolerability leading to strong uptake in the post-chemo setting. Indication expansion to include the pre-chemo setting, competing with Dendreon’s Provenge (sipuleucel- T), represents a key opportunity to expand the patient base for these therapies. Entry of these new therapies has pushed Jevtana’s (cabazitaxel; Sanofi) use later in the treatment algorithm. However, hormone therapies and Taxotere (docetaxel; Sanofi) remain the standard of care in post radiation/surgery and chemotherapy settings respectively;

Competition will intensify in all disease segments – The prostate cancer market is set to become increasingly crowded with near-term and longer-term drug launches. In the post radiation/surgery setting, Xtandi is expected to compete with anti-androgen’s, while in the pre and post-chemo segments new therapies TAK-700 (orteronel;Takeda/Millennium), Yervoy (ipilimumab; Bristol- Myers Squibb) and Alpharadin (radium-233 dichloride; Algeta/Bayer) will compete with or complement Xtandi and Zytiga. Pipeline immunotherapy Prostvac (Bavarian Nordic) will present real competition for Provenge in pre-chemo segment, while cabozantinib (Exelixis) will be used as a last-line treatment option in patients to improve metastatic lesions on bones;

Influx of new therapies will result in evolution of clinical trials – KOLs expect future clinical trials to include an active comparator, instead of placebo, and greater emphasis will be placed on progression free survival as newer therapies enter the market. Other trends include the phasing out of over diagnosis, development of new novel androgen targeting therapies, and biomarkers.

Report Details:

KOL Insight: Prostate Cancer: Competition intensifies in race to the top
Published: March, 2013
Pages: 135
Price: US$ 4,995.00

More information can be found in the report “KOL Insight: Prostate Cancer: Competition intensifies in race to the top” by FirstWord.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970